FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

VYKAT XR was approved by the FDA on March 26, 2025, for treating hyperphagia in PWS patients aged 4 and older. Common adverse reactions included hypertrichosis, edema, hyperglycemia, and rash.

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ:SLNO), whose stock has surged 116% over the past year and is trading near its 52-week high of $85.36, presented new data on VYKAT XR (diazoxide ...

The research firm highlighted Vykat XR as the first-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder. TD Cowen noted that the drug "bucked the trend of ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...

In April 2025, Vykat XR featured an extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide. While its precise mechanism of action remains uncertain, ...